论文部分内容阅读
目的:探讨联合术前介入及芦荟大黄素治疗方案在子宫内膜癌治疗中的应用效果。方法:以150例行手术治疗的子宫内膜癌患者作为观察对象,并随机将患者分为术前接受介入治疗的对照组及术前接受介入联合术后芦荟大黄素治疗者为观察组,每组75例。对比两组临床治疗效果及治疗副作用发生率。结果:两组接受手术治疗前生存质量评分(FACT-G-V4评分)比较未见统计学差异(P>0.05),而手术3个月后,观察组FACT-G-V4评分明显低于对照组(P<0.05)。同时观察组术后3个月内治疗并发症的发生率与对照组比未见统计学差异(P>0.05)。而观察组术后1年、2年及3年肿瘤复发率均明显低于对照组(P<0.05)。此外,观察组术后1年、2年及3年生存率明显高于对照组(P<0.05)。结论:术前接受介入联合术后芦荟大黄素治疗可显著的改善子宫内膜癌患者临床治疗效果,且并不提高术后并发症的发生率。
Objective: To investigate the combined effect of preoperative intervention and aloe-emodin in the treatment of endometrial cancer. Methods: 150 cases of endometrial cancer patients undergoing surgery as the observation object, and patients were randomly divided into preoperative control group received interventional therapy and preoperative interventional surgery combined with aloe-emodin treatment for the observation group, each Group of 75 cases. Compare the two groups of clinical treatment and treatment of side effects. Results: There was no significant difference in quality of life before surgery (FACT-G-V4 score) between the two groups (P> 0.05). After 3 months of operation, the score of FACT-G-V4 in the observation group was significantly lower than that of the control Group (P <0.05). In the meantime, there was no significant difference in the incidence of complication between the observation group and the control group within 3 months (P> 0.05). The tumor recurrence rates in the observation group at 1 year, 2 years and 3 years after operation were significantly lower than those in the control group (P <0.05). In addition, the 1-year, 2-year and 3-year survival rates in the observation group were significantly higher than those in the control group (P <0.05). Conclusions: Preoperative treatment with aloe-emodin after interventional therapy can significantly improve the clinical efficacy of endometrial cancer patients without increasing the incidence of postoperative complications.